The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1681
July 24, 2023
View Complete Issue         Table of Contents 2019 
Zavegepant (Zavzpret) for Acute Treatment of Migraine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Zavegepant (Zavzpret) for Acute Treatment of Migraine
July 24, 2023 (Issue: 1681)
The FDA has approved zavegepant nasal spray (Zavzpret – Pfizer) for acute treatment of migraine with or without aura in adults. Zavzpret is the first nasal spray formulation of a calcitonin gene-related peptide (CGRP) receptor antagonist...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Zavegepant (Zavzpret) for Acute Treatment of Migraine
Article code: 1681c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.